vTv Therapeutics Inc.
For the period ended May 13, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 13, 2026 · Filed May 13, 2026
VTVT$21.03-3.3%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except per share data)
(in thousands, except per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| Revenue | $36,839 | $— |
| Operating expenses: | ||
| Research and development | 8,978 | 2,830 |
| General and administrative | 4,598 | 3,673 |
| Total operating expenses | 13,576 | 6,503 |
| Operating income/(loss) | 23,263 | (6,503) |
| Interest income | 838 | 331 |
| Other income (expense), net | 33 | (45) |
| Net income (loss) before income taxes and noncontrolling interest | 24,134 | (6,217) |
| Income tax provision | — | — |
| Net income (loss) before noncontrolling interest | 24,134 | (6,217) |
| Less: net loss attributable to noncontrolling interest | — | (1,125) |
| Net income (loss) attributable to vTv Therapeutics Inc. | $24,134 | $(5,092) |
| Net income (loss) attributable to vTv Therapeutics Inc. common shareholders | $24,134 | $(5,092) |
| Basic net income (loss) per share of vTv Therapeutics Inc. Class A common stock | $1.94 | $(0.77) |
| Basic weighted average number of vTv Therapeutics Inc. Class A common stock | 12,409,278 | 6,582,844 |
| Diluted net income (loss) per share of vTv Therapeutics Inc. Class A common stock | $1.65 | $(0.77) |
| Diluted weighted average number of vTv Therapeutics Inc. Class A common stock | 14,634,420 | 6,582,844 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.